Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanistic study of finerenone in delaying progression of diabetic kidney disease
ChiCTR2600124203Phase 4Recruiting
- Sponsor
- Shanxi Provincial People's Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of finerenone in diabetic glomerulosclerosis (2 arms), sponsored by Shanxi Provincial People's Hospital. Primary endpoints: Serum creatinine, Urinary albumin/creatinine ratio (UACR) and 5 more. Started May 2026; status: recruiting.
02
Drugs
finerenone
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on ChiCTR2600124203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124203.